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BACKGROUND: Stereotactic body radiotherapy (SBRT) is an alternative to surgery for clinical stage I non–small cell lung cancer
(NSCLC), but comparing its effectiveness is difficult because of differences in patient selection and staging. METHODS: Two data-
bases were combined which contained patients treated from 1999 to 2008 by lobectomy (LR, n5 132), sublobar resection (SLR,
n548), and SBRT (n5 137) after negative staging. Univariate and multivariate analysis were performed for survival (OS), total recur-
rence control (TRC comprises local-regional and distant control), and locoregional control (LRC) in our entire population. A matched-
pair analysis was also performed that compared surgery and SBRT results. Median follow-up for the entire study population was 25.8
months. RESULTS: On univariate analysis, OS was significantly worse with SBRT and also correlated with histology, the Charlson
comorbidity index, tumor size, and aspirin use; TRC correlated only with histology; and no variable significantly correlated with LRC.
OS was significantly poorer for SBRT in the matched-pair analysis than for patients treated with surgery, but TRC and LRC were not
significantly different between these groups. Multivariate analyses including propensity score as a covariate (controlling for all factors
affecting treatment selection) found that OS correlated only with Charlson comorbidity index, and TRC correlated only with tumor
grade. LRC correlated only with tumor size with or without propensity score correction. CONCLUSIONS: This retrospective study has
demonstrated similar OS, LRC, and TRC with SBRT or surgery after controlling for prognostic and patient selection factors. Random-
ized clinical trials are needed to better compare the effectiveness of these treatments. Cancer 2013;119:2683–91. VC 2013 American
Cancer Society.
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INTRODUCTION
Since 1962, lobectomy (LR) has been considered to be an acceptable alternative to pneumonectomy for patients with clin-
ical stage I non–small cell lung cancer (NSCLC) when tumors can be removed with negative resection margins.1 A pro-
spective, randomized trial demonstrated the inferiority of sublobar resection (SLR) to LR with regards to local control and
survival, with no difference between the 2 in the risk of surgical complications or postoperative lung function.2 Therefore,
SLR is generally recommended only for select populations or patients unable to tolerate a LR.3
Stereotactic body radiotherapy (SBRT), also referred to as stereotactic ablative body radiation (SABR), deliv-
ers very high radiation doses to restricted volumes over 1 to 5 treatment days using multiple precisely aimed
radiotherapy beams. This approach has emerged as an alternative to surgery for medically inoperable patients with
early-stage cancers. Studies at individual centers4,5 and a multi-institutional investigation conducted by the Radia-
tion Therapy and Oncology Group (RTOG)6 have demonstrated excellent rates of locoregional control (LRC),
disease-free survival, and overall survival (OS). This success has raised the issue of whether SBRT/SABR might be
equally effective as surgery for medically fit patients. However, there are clearly substantial differences between
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patients treated with surgery or SBRT/SABR in retro-
spective series with regard to age, performance status,
comorbid medical conditions, and so forth, that make
direct comparisons of results problematic.
We therefore sought to compare results of SBRT/
SABR to surgery for patients with stage I NSCLC by iden-
tifying prognostic factors and then using these factors in
performing a matched-pair analysis to try to correct for at
least some of the biases in treatment assignment between
these modalities. Our results suggest that the 2 approaches
provide similar OS, LRC, and TRC, which supports per-
forming a phase III trial comparing these two treatment
techniques.
MATERIALS AND METHODS
We combined de-identified databases of lung cancer
patients from 4 institutions where 639 patients underwent
surgical resection from 1999 to 20087,8 and 1 institution
where 137 patients underwent SBRT/SABR9 from 2000
to 2008. One hundred eighty patients were in the surgical
group. 180 resections (132 treated with LR and 48 with
SLR, all wedge resections) had negative preoperative stag-
ing with PET-CT (no ct/pet performed in 87), negative
lymph nodes at surgery (node positive 117), T1-T2
tumors (161 T3-T4) and pathologically-confirmed squa-
mous cell, adenocarcinoma, or non–small cell “not other-
wise specified” (NOS) histology (other histologies5 79)
who did not received adjuvant or neoadjuvant chemother-
apy (chemotherapy received by 181) or radiotherapy. All
SBRT/SABR patients included in our analysis received a
minimum prescription tumor dose of 100 Gy10
10 and
had biopsy-proven NSCLC, but did not undergo lymph-
adenectomy or lymph node staging. The mean dose was
60 Gy in 3 fractions. Range of doses was 48 to 60 Gy in 3
to 5 fractions. Three-dimensional treatment planning was
used to stereotactically direct a total of 10 to 12 non-co-
planar, nonopposed beams to deliver the dose to the PTV.
Pencil beam algorithm and no heterogeneity corrections
were used in the first 102 patients. The last 35 patients
were treated with a collapsed-cone algorithm and hetero-
geneity corrections.
Table 1 compares the characteristics of the SBRT/
SABR and 3 surgical groups. The SBRT/SABR patients
were older and had significantly higher mean values
(assessed by the unpaired t test) for tumor diameter
(P5 .012), age (P< .001), and Charlson comorbidity
index11 (P< .001) than the surgery patients. The propor-
tion of tumors described as NSCLC-NOS was higher in
the SBRT/SABR patients (43%, or 59 of 137) compared
to the surgery patients (8%, or 14 of 180).
Statistical Analysis
We evaluated factors potentially affecting OS, TRC, and
LRC in the combined set of 137 SBRT/SABR patients and
180 surgery patients. Local and locoregional control were
defined as the absence of any recurrence in the ipsilateral
lung, and the ipsilateral lung, bronchial stump/suture line,
and N1-N3 nodal areas respectively. Total recurrence con-
trol was defined by the absence of any recurrence (local, re-
gional, or disseminated). Follow-up times used for OS,
LRC, and TRC were from the date of surgery or last day of
SBRT. Ipsilateral pulmonary recurrences were only
included as a local recurrence if the involved physicians were
certain that this tumor was recurrent. In equivocal cases, we
considered the tumor to be a second primary cancer and
censored the patient from our study group.7,8
Overall survival was defined as being alive with or with-
out disease. The Kaplan-Meier method was used to calculate
survival/control rates. Univariate comparisons of these esti-
mates were performed using the log-rank test. A P value of
0.05 was chosen to represent statistical significance. Match-
pairs were constructed for evaluation of TRC, LRC, and dis-
seminated control by matching by pathology, age, size and
sex, but not Charlson comorbidity index or aspirin use,
which were used only for the OS matched-pair analysis. All
matching was performed in a 1:1 ratio. Age and tumor size
were not dichotomized in the matching, but were evaluated
as continuous variables. Multivariate analysis was performed
using Cox proportional hazards analysis. To correct for
potential bias in the selection of SBRT/SABR versus surgery
within the multivariate analysis, we created a logistic regres-
sion model of the probability of selecting SBRT/SABR and
included it as a covariate in themultivariate analysis.12,13
Median follow-up for the entire study population
was 25.8 months (range, 3-73 months). The median fol-
low up was 18.8 months for SBRT and 30.0 months for
surgery. The median lengths of follow-up for living
patients were 18.8, 35.0, and 31.0 months for the SBRT/
SABR, sublobar resection, and lobectomy patients respec-
tively, with 66%, 90%, and 89% having been followed
for 12 or more months, respectively.
RESULTS
The 2-year actuarial rates of OS, DFS, and LRC for the
entire population of 317 patients were 76.8%, 79.9%,
and 88.8%, respectively. The respective 5-year OS, DFS,
and LRC rates were 44.6%. 53.0%, and 77.0%. A total of
74 (54.0%), 13 (27.1%), and 27 (20.4%) patients died in
the SBRT, SLR, and LR groups, respectively. 15, 6, and 18
locoregional failures were seen in the SBRT, SLR, and LR
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groups, respectively, and distal failure occurred in 21, 4, and
14 patients in the SBRT, SBLR, and LR groups, respectively.
Matched-Pair Analysis
Factors chosen for the matched-pair analysis were drawn
from univariate analysis of OS, TRC and LRC shown in
Table 2.We found that overall survival significantly corre-
lated with histology, Charlson comorbidity index, tumor
size, aspirin use, and SBRT/SABR. Univariate analysis
also correlated TRC with histology. No variables signifi-
cantly correlated with LRC, although the closest was tu-
mor size: P5 .060 (Fig. 1).
We constructed matched-pairs to help control for
selection bias when evaluating differences in OS by
matching pathology, age, sex, tumor diameter, aspirin use
and Charlson comorbidity index. As shown in Table 3,
Matched-pair comparisons found that OS (Fig. 2)
remained significantly poorer in SBRT/SABR patients
compared with patients undergoing either a wedge resec-
tion or a lobectomy (P5 .003, and P< .0001)
Matched-pairs were constructed for evaluation of
TRC by matching by pathology, age, size, and sex (but
not Charlson comorbidity index or aspirin use, which did
not appear to affect TRC or LRC to allow more patients
TABLE 1. Histopathologic, Treatment, and Patient Characteristics in the 4 Treatment Groups
SBRT Surgery, Both SLR and LR Sublobar Lobectomy
Variable (n5137) (n5 180) (n5 48) (n5 132)
Tumor size (cm)a 3.0 (1-7) 2.6 (1-9) 2.0 (1-4) 2.5 (1-9)
Age, y a 73.3 (51-92) 68.3 (38-87) 67.5 (38-81) 68.6 (42-87)
Charlson comorbiditya 4.2 (3-10) 3.0 (0-6) 3 (1-6) 3 (0-6)
Sex (% male) 48% 55% 50% 57%
FEV1
FEV1< 80% 71% 46% 57% 42%
FEV1< 50% 64% 12% 12% 17%
FEV1< 40% 43% 7% 25% 14%
Median 46% 80% 61% 83%
Mean 49% 81% 71% 84%
DLCO
DLCO <40% 39% 13% 15% 28%
DLCO <50% 60% 32% 20% 48%
Median 45% 61% 48% 66%
Mean 46% 60% 56% 61%
Aspirin use 30% 51% 52% 50%
Adenocarcinoma 28% 61% 54% 64%
Squamous 28% 31% 38% 29%
Non–small cell, not otherwise specified 43% 8% 8% 8%
Diabetes 17% 23% 21% 24%
Hypertension 64% 66% 29% 35%
Coronary artery disease 43% 35% 35% 35%
Statin use 39% 41% 40% 41%
NSAID 40% 7% 10% 7%
Past myocardial infarct 14% 14% 13% 15%
Abbreviations: DLCO, diffusing capacity of lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; LR, lobectomy; NSAID, nonsteroidal anti-
inflammatory drug; SBRT, stereotactic body radiotherapy; SLR, sublobar resection.
a Values given as median (range).
TABLE 2. Univariate Analysis of Factors Associated
With Overall Survivala
Variable
Overall
Survival
Total
Recurrence Locoregional
Age <70 0.260 0.711 0.848
Adenocarcinoma 0.000 0.252 0.231
Non–small cell cancer, NOS 0.004 0.011 0.470
Grade 0.093 0.743 0.672
Sex 0.666 0.892 0.375
Hypertension 0.906 0.636 0.393
Coronary artery disease 0.370 0.591 0.807
Myocardial infarction 0.843 0.116 0.751
Diabetes 0.343 0.592 0.423
Steroids 0.488 0.880 0.455
Smoked within 1 mo
of operation
0.983 0.330 0.262
Aspirin 0.005 0.897 0.456
NSAID 0.379 0.620 0.751
Statin use 0.120 0.549 0.447
Lobe 0.745 0.951 0.949
Charlson comorbidity 0.001 0.544 0.603
Tumor size 0.000 0.662 0.060
SBRT/SABR versus surgery 0.000 0.288 0.944
FEV1< 80% predicted 0.220 0.450 0.174
Abbreviations: FEV1, forced expiratory volume in 1 second; NOS, not other-
wise specified; NSAID, nonsteroidal anti-inflammatory drug; SABR, stereo-
tactic ablative body radiation; SBRT, stereotactic body radiotherapy.
a Total recurrence control (locoregional and distant) and locoregional control
for the entire patient population.
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Figure 1. Actuarial analysis of overall survival is shown in 317 non–small cell lung cancer (NSCLC) patients by (A) treatment modal-
ity (137 stereotactic body radiotherapy [SBRT], 48 sublobar, and 132 lobar resections) and (B) pathology. Actuarial analyses of 317
lung cancer patients and the effects of (C) pathology on total recurrence control and (D) tumor size on locoregional control.
TABLE 3. Matched-Pair Comparison of Overall Survival (OS), Total Recurrence Control (TRC), Locoregional
Control (LRC), and Disseminated Control by Surgical Group and Stereotactic Body Radiotherapy (SBRT)
OS TRC LRC Disseminated
Treatment Modality (2, 3, and 5 y) (2, 3, and 5 y) (2, 3, and 5 y) (2, 3, and 5 y)
1. Lobectomy 2 y: 75.0% 2 y: 80.7% 2 y: 88.7% 2 y: 85.3%
3 y: 69.2% 3 y: 73.9% 3 y: 81.2% 3 y: 83.0%
5 y: 69.2% 5 y: 56.5% 5 y: 81.2% 5 y: 83.0%
2. SBRT 2 y: 66.2% 2 y: 83.3% 2 y: 87.8% 2 y: 93.1%
(match) 3 y: 40.9% 3 y: 83.3% 3 y: 87.8% 3 y: 93.1%
5 y: 33.7% 5 y: 83.3% 5 y: 87.8% 5 y: 93.1%
1 versus 2 P5.004 P5.258 P5.382 P5.382
3. SBRT 2 y: 50.8% 2 y: 95.2% 2 y: 83.6% 2 y: 92.0%
(match) 3 y: 42.3% 3 y: 78.0% 3 y: 77.1% 3 y: 92.0%
5 y: 31.7% 5 y: 78.0% 5 y: 77.1% 5 y: 92.0%
4. Wedge resection 2 y: 94.1% 2 y: 94.1% 2 y: 100% 2 y: 95.2%
3 y: 86.3% 3 y: 86.3% 3 y: 92.9% 3 y: 84.0%
5 y: 86.3% 5 y: 86.3% 5 y: 92.9% 5 y: 84.0%
3 versus 4 P5.003 P5.468 P5.059 P5.819
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to be included). As shown in Table 3, matched-pair com-
parisons of TRC, LRC and disseminated control (DC)
found no significant differences between SBRT/SABR
patients compared to lobectomy or sublobar resection
(Fig. 3).
Propensity Score
Table 4 shows the results of forward stepwise logistic
regression analysis of the probability of choosing SBRT/
SABR (versus resection). The significant variables (age, as-
pirin use, Charlson comorbidity score, diabetes, NSAID
use, non–small cell pathology, percentage predicted
FEV1, and hypertension) were included in the propensity
score (probability of choosing SBRT/SBRT) to include in
proportional hazards analysis.
Multivariate Survival Analyses
Table 5 shows the results of multivariate analysis of OS, per-
formed first without a propensity score in the first 2 columns
labeled P(OS) andHRR(OS) and then including the propen-
sity score as a covariate in the last 2 columns labeledOS1 and
HRR(OS1) to adjust for selection bias in treatment choice.
Multivariate analysis without propensity score (PS) correction
correlated better OS with surgery, lower Charlson comorbid-
ity score, and adenocarcinoma histology. After adjustment for
propensity scores, OS correlated only with Charlson comor-
bidity index (and the PS used for adjustment).
Table 6 compares multivariate analysis of total
recurrence control (TRC) without including the pro-
pensity score in the first 2 columns, P (TRC) and
HRR (TRC) to the results including the propensity
score as a covariate to control for selection bias.
Without the propensity score, we associated improved
TRC with surgery (versus SBRT/SABR) and no other
variables. With the propensity score included to con-
trol for selection bias (P5 .001), tumor grade corre-
lated with TRC at a borderline significance of
P5 .05 but SBRT/SABR did not (P5 .636). As
shown in the last two columns, there was no correla-
tion between type of therapy with LRC (P5 0.424),
which correlated only with increased tumor diameter
(P5 0.027) and a trend to older age (P5 0.052)
without propensity score included in the final model.
With the propensity score forced into the final multi-
variate model, the association with tumor diameter
retained significance (P5 .026, HRR5 1.268) and
the age association was weaker (P5 .065,
HRR5 0.973).
DISCUSSION
Themajority of patients with NSCLC present with locally
advanced disease. However, the widespread introduction
of screening patients at high risk with low-dose helical CT
may increase the number of patients found with early-
Figure 2. Matched-pair comparison is shown of overall sur-
vival with stereotactic body radiotherapy (SBRT) versus (A)
sublobar resection, (B) lobectomy, or (C) any surgery.
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stage disease.14,15 Hence, it is important to determine
how this increasing patient population will be treated.
Currently, 2 open prospective trials randomize patients to
either surgery or SBRT/SABR. A trial at the MD Ander-
son Cancer Center, Houston, Texas, includes patients
with stage I NSCLC measuring less than 4 cm, who are
treated with either SBRT/SABR or surgery (LR or pneu-
monectomy), with the primary outcome being OS at 3
years. The American College of Surgeons Oncology
Group/Radiation Therapy Oncology Group trial Z4099/
1021 (ClinicalTrials.gov identifier: NCT01336894) will
randomly allocate patients with stage I NSCLC (smaller
than 3 cm) to SLR with or without brachytherapy or to
SBRT/SABR, with the primary outcome being OS at 3
years. However, the estimated completion date of the
former trial is December 2017, and the latter trial
just began recruiting patients in 2011.16 Because the
results of these trials, if completed, will not be avail-
able for quite some time, we feel that retrospective
reviews like our may provide some clues to how
these patients with early-stage lung cancer can be
best managed. Unfortunately, the ROSEL trial which
was conducted at Vrije Universiteit, Amsterdam,
Netherlands, and randomized patients with stage IA
Figure 3. Matched-pair comparison is shown of total recurrence control with stereotactic body radiotherapy (SBRT) versus (A)
sublobar resection, (B) lobectomy, (C) any surgery. Matched-pair comparison is shown of locoregional control with SBRT versus
(A) sublobar resection or (C) lobectomy
TABLE 4. Logistic Regression Prediction of Treat-
ment Selection (Propensity) for Stereotactic Body
Radiotherapy/Stereotactic Ablative Body Radiation
(Radiosurgery) as Opposed to Surgical Resectiona
Variable P OR 95% CI for OR
Age (per y) .0000 1.148 (1.077-1.22)
Aspirin use .0000 0.099 (0.032-0.307)
Charlson comorbidity .0000 6.474 (3.47-12.077)
Diabetes .0000 0.084 (0.023-0.309)
NSAID use .0000 60.058 (13.614-264.9)
Pathology: non–small
cell cancer
.0010 7.102 (2.154-23.41)
FEV1 % predicted .0050 0.968 (0.946-0.99)
Hypertension .0190 0.282 (0.098-0.811)
Chronic steroid use .3970 NS
Coronary artery disease .6370 NS
Location .9150 NS
Pathology: adenocarcinoma .7720 NS
Pathology: squamous .7720 NS
Prior myocardial infarct .5700 NS
Sex (male) .5000 NS
Smoked< 1 mo before
procedure
.2630 NS
Statin use .3400 NS
Tumor grade .7340 NS
Tumor size .2040 NS
Abbreviations: FEV1, forced expiratory volume in 1 second; NS, not signifi-
cant; NSAID, nonsteroidal anti-inflammatory drug.
aOdds ratios (ORs) and respective 95% confidence intervals (CIs) are for
significant variables only.
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NSCLC to surgery or SBRT was recently closed due
to poor accrual.16 Our analysis suggests that SBRT/
SABR and surgery will likely yield the same OS,
TRC, and LRC in such patients. However, we
strongly encourage enrollment in the ongoing
randomized trials.
TABLE 5. Multivariate Proportional Hazards Analysis (Without Case-Control Matching) for Overall Survival
(OS) Without and With (1) Propensity Score Correction Predicting Selection of Stereotactic Body Radio-
therapy/Stereotactic Ablative Body Radiation (Radiosurgery)
Variable P (OS) HRR (OS), (CI) P (OS1) HRR (OS1), (CI)
Propensity for SBRT NI NI .002 2.70 (1.42-5.13)
SBRT/SABR .006 1.98 (1.12-3.30) .238 NS
Age .557 NS .56 NS
Aspirin use .177 NS .291 NS
Charlson comorbidity .011 1.27 (1.06-1.52) .043 1.22 (1.01-1.48)
Chronic steroid use .901 NS .768 NS
Coronary artery disease .406 NS .411 NS
Type 1 diabetes .929 NS .448 NS
FEV1 % predicted .529 NS .328 NS
Hypertension .591 NS .339 NS
Lobe 1up2mid3low .569 NS .634 NS
NSAID use .622 NS .652 NS
Past myocardial infarct .535 NS .355 NS
Pathology: adenocarcinoma .037 0.63 (0.40-0.97) .072 NS
Pathology: non–small cell .464 NS .896 NS
Pathology: squamous .464 NS .065 NS
Sex: male .826 NS .727 NS
Smoked< 1 mo before procedure .887 NS .801 NS
Statin use .158 NS .3 NS
Tumor grade .958 NS .44 NS
Tumor size .426 NS .134 NS
Abbreviations: CI, 95% confidence interval; FEV1, forced expiratory volume in 1 second; HRR, hazard rate ratio; NI, covariate not included; NS, not significant;
SABR, stereotactic ablative body radiation; SBRT, stereotactic body radiotherapy.
TABLE 6. Multivariate Proportional Hazards Analyses (Without Case-Control Matching) of Total Recurrence
Control (TRC) and Locoregional Control (LRC) Without and With (1) Propensity Score Correction Predict-
ing Selection of SBRT/SABR (Radiosurgery)
Variable P (TRC) HRR (TRC), (CI) P (TRC1) HRR (TRC1), (CI) P (LRC1) HRR (LRC1), (CI)
Propensity for SBRT NI NI .001 2.78 (1.49-5.19) .142 NS
SRS/SABR .008 2.01 (1.2-3.4) .636 NS .424 NS
Age .646 NS .655 NS .052 0.97 (0.94-1.00)
Aspirin use .653 NS .724 NS .520 NS
Coronary artery disease .489 NS .583 NS .208 NS
Charlson comorbidity .085 NS .284 NS .069 NS
Chronic steroid use .46 NS .688 NS .095 NS
Diabetes .783 NS .814 NS .692 NS
FEV1 % .764 NS .539 NS .594 NS
Hypertension .475 NS .408 NS .286 NS
Location .863 NS .72 NS .416 NS
Prior myocardial infarct .434 NS .295 NS .519 NS
NSAID use .372 NS .188 NS .641 NS
Pathology: squamous .25 NS .254 NS .589 NS
Pathology: adenocarcinoma .97 NS .742 NS .153 NS
Pathology: non–small cell .172 NS .08 NS .254 NS
Sex: Male .172 NS .218 NS .458 NS
Smoke< 1 mo before procedure .94 NS .818 NS .198 NS
Statin use .715 NS .761 NS .227 NS
Tumor grade .133 NS .050 0.169 (1.00-1.9) .455 NS
Tumor size .911 NS .686 NS .027 1.27 (1.03-1.58)
Abbreviations: CI, 95% confidence interval for HRR; HRR, hazard rate ratio; NI, covariate not included; NS, not significant; NSAID, nonsteroidal anti-inflamma-
tory drug.
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Although, we tried to match patients treated with
SBRT/SABR and surgery as best possible for prognostic
variables, there are inevitably limitations to the ability of
such an analysis, no mater how carefully done. Because
patients receiving SBRT/SABR undergo biopsies and not
a surgical resection, it is difficult to determine known
prognostic factors such as tumor grade,17,18 lymphatic
vascular invasion,17,19 and accurate histology.7 It should
be noted that NSCLC-NOS is a diagnosis of exclusion
and is discouraged.20 Because of the small biopsy samples
associated with the SBRT/SABR patients, this patient
group had a much greater percentage of NSCLC-NOS
(44%) than in either surgical group (8% in both). In gen-
eral, it is recommended that NSCLC-NOS be used as lit-
tle as possible and only when a more specific tissue
diagnosis is not available by morphology or special
stains.20 Nevertheless, our multivariate analysis for OS
showed a statistically significant better outcome for
adenocarcinomas which may have been due to the overuse
of NSCLC-NOS in the SBRT/SABR group because of
small biopsy samples. However, after adjustment for pro-
pensity score which took into to account the overuse of
the term NSCLC-NOS in the patients treated with
SBRT/SABR, histology was no longer significant for OS,
but Charlson Comorbidity Index was significant. CCI is
used to predict 10-year mortality for a patient due to 22
comorbid conditions, such as heart disease, cancer, de-
mentia, liver disease, hemiplegia, and others.11 CCI has
been validated in patients with NSCLC.21 In addition,
because none of the SBRT/SABR patients underwent a
nodal staging or dissection, the nodal status of these
patients was unknown. Although the American College of
Surgeons Oncology Group (ACOSOG) Z003 trial found
no difference in 6-year OS, 5-year disease-free survival,
local recurrence, regional recurrence, or distant recurrence
rates between patients randomized to mediastinal lymph
node dissection versus mediastinal lymph node sam-
pling,22 the prognostic detriment of nodal involvement
has been well established.23,24
For survival, we used pathology, age, sex, tumor size,
aspirin use, and Charlson comorbidity score for the MPC
based on our matched-pair analysis and known prognostic
factors for survival in the literature (the same factors with
the exclusion of Charlson comorbidity index and aspirin
use were used for the MPC for LRC and TRC). We felt
that additional parameters were needed for the MPC in
regards to OS because of the results of our univariate anal-
yses and because the SBRT/SABR patients were all medi-
cally inoperable and were selected for this treatment
modality because of their survival limitation. Needless to
say, the OS results were still significantly worse for SBRT/
SABR versus lobectomy when the MPC for survival was
originally performed without including aspirin use and
Charlson comorbidity status (results not shown). How-
ever, once we adjusted the multivariate analysis for selec-
tion factors that were used for selection of SBRT/SABR
(PS adjustment), there was no longer a survival advantage
to surgery.
Multivariate analyses with adjustment for treatment
selection did not reveal that SBRT/SABR was associated
with TRC or LRC. Tumor grade and size were only fac-
tors significantly associated with TRC and LRC.
It should be noted that the database of surgically-
treated patients contains patients from 4 different aca-
demic practices as per our previous publications,7,8 but
the SBRT/SABR database contains patients from only
one institution. Because SBRT/SABR is a new technique
that treats a largely poor-prognostic, medically-inoperable
patient group, long patient follow-up can be difficult. We
chose SBRT data from one institution because of the
known relatively long follow-up at this cancer treatment
facility. We acknowledge that having SBRT/SABR
patients from one skilled institution may bias our results
in favor of SBRT, but the techniques developed at this
institution have shown the same high levels of control in a
multi-institution phase 2 trial.6
Using a propensity score to account for selection
bias in the multivariate analysis provides the ability to
control for the effects of greater numbers of variables and
conduct the analysis in a larger number of subjects. Our
multivariate analysis with propensity scores to control for
selection bias cast doubt on any differences in overall sur-
vival, total recurrence control or local-regional control
between SBRT/SABR and surgical resection.
CONCLUSIONS
Patients with stage I NSCLC treated with SBRT/SABR
had similar TRC and LRC as patients treated with surgery
but worse OS, on a matched-pair analysis. However, after
adjustment for treatment selection, overall survival was no
longer significantly worse for patients treated by SBRT/
SABR. Our results suggest that randomized trials are
needed to eliminate selection bias in treatment assignment
in order to accurately compare outcomes between these
approaches. We greatly encourage the completion of the
ongoing prospective, randomized trials comparing SBRT/
SABR to surgery.
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